HOME / Blog

GeneGoCell Insights

Stay informed, stay productive with all the latest from GeneGoCell.

All Genome Editing Safety Genome Editing Verification Off-target Analysis Chromosomal Translocation Analysis Cell and Gene Therapy FDA Gene Therapy Guidance G-Screen℠ G-LMP℠ G-Int℠ GEV℠ Genome Editing Integration Analysis Integration Site Analysis Transgene Integrity Genome Editing Ethics Independent Verification G-Trans℠ Genome Editing Translocation Analysis On-target Verification G-Amp℠ G-GUIDE℠ Off-Target analysis CRISPR off-target identification Cell And Gene Therapy G-Amp-HT℠ High-Throughput NGS Genotyping Clone Genotyping NGS Testing Cell Line Engineering in vivo CAR CAR cell therapy CAR cell therapy beyond cancer CGT testing Genomics Biotech Entrepreneurship
G-GUIDE℠ Off-Target Analysis: High-Sensitivity CRISPR Off-Target Identification with Optimized GUIDE-Seq

G-GUIDE℠ Off-Target Analysis: High-Sensitivity CRISPR Off-Target Identification with Optimized GUIDE-Seq

By Dr. Aaron Zhang-Chen, CQA, PhD, CTO at GeneGoCell on September 7, 2026

Learn how GeneGoCell’s licensed G-GUIDE℠ workflow enables genome-wide CRISPR off-target identification with 0.005% LOD and under two-week turnaround time.
G-GUIDE℠Off-Target analysisCRISPR off-target identificationGenome Editing VerificationGenome Editing SafetyCell And Gene Therapy
What Must Be Measured, and What Can Be Shared: NGS, prior knowledge, and genome-editing safety in three 2026 FDA publications

What Must Be Measured, and What Can Be Shared: NGS, prior knowledge, and genome-editing safety in three 2026 FDA publications

By Dr. Aaron Zhang-Chen, CQA, PhD on August 31, 2026

What do three 2026 FDA guidance/recommendation mean for genome editing? Learn what NGS safety data should be measured, what prior knowledge can be reused, and when.
Genome Editing SafetyGenome Editing VerificationOff-target AnalysisChromosomal Translocation AnalysisCell and Gene TherapyFDA Gene Therapy Guidance
Evidence Before Hope: Safety, Ethics, Independent Verification, and Public Education in Genome Editing

Evidence Before Hope: Safety, Ethics, Independent Verification, and Public Education in Genome Editing

By Dr. Elizabeth Yan Zhang, CMQ/OE, MBA, PhD, Founder and CEO, GeneGoCell on July 27, 2026

Genome editing requires rigorous safety data, ethical oversight, independent verification, transparent reporting, and accessible public education before clinical translation.
Genome Editing SafetyGenome Editing VerificationGenome Editing EthicsIndependent Verification